Improving hepatitis C therapy: Attaching a polyethylene glycol "tail" to interferon for better clinical properties

Modern Drug Discovery

Volumn 3, Issue 7, 2000, Pages 59-67

  Charles, Stephen A ^a   Harris, J Milton ^a   Pedder, Simon ^a   Kumar, Saran ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001899594     PISSN: 10998209     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Chronic Hepatitis C: Current Disease Management www.niddk.nih.gov/ health/digest/pubs/chrnhepc/chrnhepc.htm (accessed July 15, 2000).
2. Liang, T. J. et al. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 2000, 132 (4), 296-305.
3. Wills, R. J. Clinical pharmacokinetics of interferons. Clin. Pharmacokinet. 1990, 19, 390-399.
4. Zhi, J. et al. Influence of human serum albumin content in formulations on the bioequivalency of interferon alfa-2a given by subcutaneous injection in healthy male volunteers. J. Clin. Pharmacol. 1995, 35 (3), 281-284.
5. Bailon, P.; Berthold, W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharmaceut. Sci. Technol. Today 1998, 1, 352-356.
6. Fuertges, F.; Abuchowski, A. The clinical efficacy of polyethylene glycol-modified proteins. J. Controlled Release 1990, 11, 139-148.
7. Harris, N. J. et al. Multiarmed, Monofunctional Polymer for Coupling to Molecules and Surfaces. U.S. Patent 5,932,462, Aug 3,1999.
8. Gilbert, C. W.; Park-Cho, M. O. Interferon Polymer Conjugates. U.S. Patent 5,951,974, Sept 14, 1999.
9. Zaplipsky, S.; Lee, C. Use of functionalized poly(ethylene glycol)s for modification of polypeptides. In Poly(ethylene glycol) chemistry. Biotechnical and biomedical applications; Harris, J., Ed.; Plenum Press: New York, 1992; pp 347-370.
10. O'Brien, C. et al. A double-blind, multicenter, randomized, parallel dose-comparison study of six regimens of 5kD, linear peginterferon alfa-2a compared with Roferon-A in patients with chronic hepatitis C [abstract]. Presented at the International Conference on Therapies for Viral Hepatitis, Maui, HI, Dec 6, 1999.
11. Ballon, P. et al. Pharmacological properties of five polyethylene glycol conjugates of interferon alfa-2a [abstract]. Presented at the International Conference on Therapies for Viral Hepatitis, Maui, HI, Dec 6, 1999.
12. Fung, W-J.; Porter, J.; Bailon, P. Strategies for the Preparation and Characterization of Polyethylene Glycol (PEG) Conjugated Pharmaceutical Protein. Poly. Prepr. (Am. Chem. Soc., Div. of Fuel Chem.) 1997, 38, 565-566.
13. Algranati, N. E.; Sy, S.; Modi, M. A branched methoxy 40-kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics of peginterferon alpha-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C. Hepatology 1999, 40 (Suppl), 190A.
14. McHutchison, J. G. et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med 1998, 339, 1485-1492.
15. Poynard, T. et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998, 352, 1426-1432.
16. Heathcote, E. J. et al. Multinational evaluation of the efficacy and safety of once-weekly peginterferon α-2a (PEG-IFN) in patients with chronic hepatitis C (CHC) with compensated cirrhosis. Hepatology 1999, 30 (4Pt2), 316A.
17. Shiffman, M. et al. A controlled, randomized, multicenter, ascending dose phase II trial of Pegylated interferon alfa-2a (PEG) vs standard interferon alfa-2a (IFN) for treatment of chronic hepatitis C [Abstract no. L0418]. Gastroenterology 1999, 116, Part 2, 1275.